Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Announce Exit from Pharmaceutics International, Inc. A consortium of investors, including Pharmascience Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience has successfully exited its equity stake in Pharmaceutics…
Dr. Hong Jiang: Advancing Immunology from Scientific Breakthroughs to Clinical Applications Dr. Hong Jiang, MD, PhD, has been recognized in Marquis Who’s Who for her outstanding contributions to immunology and biomedical research. Marquis Who’s Who selects individuals based on their…
Claxton Copeland III Recognized for Excellence in Clinical Research Claxton Copeland III has been selected for inclusion in Marquis Who’s Who, a prestigious recognition that highlights individuals based on their accomplishments, visibility, and impact within their respective fields. His selection…
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data for PP-007 in AIS at 2025 ISC Phase 1 Data Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, is poised to make a significant contribution to the field of acute ischemic stroke (AIS)…
Turn Therapeutics Achieves 24-Hour Stability for Intranasal Live Vaccine at Room Temperature Turn Therapeutics has made a groundbreaking achievement in vaccine preservation by successfully maintaining the viability of a live vaccine for 24 hours at room temperature using its innovative…
Africa and Europe Unite to Revolutionize RNA-Based Vaccines and Therapeutics Production In a groundbreaking collaboration, Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding (MoU) to establish an innovative end-to-end RNA-based vaccine and…
Cardio Diagnostics Expands Reach with New Partnerships to Transform Heart Disease Prevention and Management Cardio Diagnostics Holdings a leading company in AI-driven Precision Cardiovascular Medicine, has announced the expansion of its innovative solutions with seven new provider partnerships. This strategic…
OS Therapies a clinical-stage biotechnology company focused on developing immunotherapies and targeted drug conjugates to treat cancer, has provided a comprehensive update to the market regarding its recent achievements and plans for the future. This announcement comes on the heels…
Cagent Vascular Announces the Launch of Serranator SL-PRO™ for Pedal and Tibial Disease Treatment Cagent Vascular a leader in the development of cutting-edge serration technology for vessel dilation in endovascular procedures, has unveiled its latest innovation: the Serranator SL-PRO™ PTA…
TriLink BioTechnologies® and Avantor® Partner to Expand Nucleic Acid Solutions in Europe TriLink BioTechnologies a Maravai® LifeSciences company and a global leader in providing cutting-edge life science reagents and services, has announced a strategic partnership with Avantor a renowned global…
D&D Pharmatech a clinical-stage biotechnology company dedicated to the development of disease-modifying therapeutics, has announced the successful completion of patient enrollment for DD01-DN-2, an ongoing Phase 2 clinical trial. This trial is designed to assess the efficacy and safety of…
Phase 3 Trial Pfizer has announced significant and positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER clinical trial. This trial assessed the efficacy of BRAFTOVI® in combination with cetuximab, marketed as ERBITUX®, and mFOLFOX6,…